BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

490 related articles for article (PubMed ID: 25851829)

  • 41. Risk factors for second primary malignancies following thyroid cancer: a nationwide cohort study.
    Kim M; Kim H; Park S; Joo J; Kim IJ; Kim BH
    Eur J Endocrinol; 2022 Apr; 186(5):561-571. PubMed ID: 35286279
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Development of second primary malignancy in patients with non-Hodgkin lymphoma: a nationwide population-based study.
    Chien SH; Liu CJ; Hong YC; Teng CJ; Hu YW; Ku FC; Yeh CM; Chiou TJ; Gau JP; Tzeng CH
    J Cancer Res Clin Oncol; 2015 Nov; 141(11):1995-2004. PubMed ID: 25971624
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Shortened telomere length in peripheral blood leukocytes is associated with cumulative radioactive iodine doses in patients with differentiated thyroid carcinoma.
    Choi H; Cho SW; Kim HH; Yi KH; Park DJ; Park YJ
    Cancer; 2024 Jun; 130(12):2215-2223. PubMed ID: 38376914
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Risk of salivary gland cancer after childhood cancer: a report from the Childhood Cancer Survivor Study.
    Boukheris H; Stovall M; Gilbert ES; Stratton KL; Smith SA; Weathers R; Hammond S; Mertens AC; Donaldson SS; Armstrong GT; Robison LL; Neglia JP; Inskip PD
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):776-83. PubMed ID: 22836059
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Risk of developing chronic myeloid neoplasms in well-differentiated thyroid cancer patients treated with radioactive iodine.
    Molenaar RJ; Pleyer C; Radivoyevitch T; Sidana S; Godley A; Advani AS; Gerds AT; Carraway HE; Kalaycio M; Nazha A; Adelstein DJ; Nasr C; Angelini D; Maciejewski JP; Majhail N; Sekeres MA; Mukherjee S
    Leukemia; 2018 Apr; 32(4):952-959. PubMed ID: 29104287
    [TBL] [Abstract][Full Text] [Related]  

  • 46. The risk of second primary malignancies up to three decades after the treatment of differentiated thyroid cancer.
    Brown AP; Chen J; Hitchcock YJ; Szabo A; Shrieve DC; Tward JD
    J Clin Endocrinol Metab; 2008 Feb; 93(2):504-15. PubMed ID: 18029468
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Risk of a second malignant neoplasm among 5-year survivors of cancer in childhood and adolescence in British Columbia, Canada.
    MacArthur AC; Spinelli JJ; Rogers PC; Goddard KJ; Phillips N; McBride ML
    Pediatr Blood Cancer; 2007 Apr; 48(4):453-9. PubMed ID: 16767718
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Role of low-cost thyroid follow-up in children treated with radiotherapy for primary tumors at high risk of developing a second thyroid tumor.
    Piccardo A; Foppiani L; Puntoni M; Hanau G; Calafiore L; Garaventa A; Arlandini A; Villavecchia G; Bianchi P; Cabria M
    Q J Nucl Med Mol Imaging; 2012 Oct; 56(5):459-67. PubMed ID: 23090072
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Increased risk of second primary malignancies in patients with gynecological cancer. A Swedish record-linkage study.
    Bergfeldt K; Einhorn S; Rosendahl I; Hall P
    Acta Oncol; 1995; 34(6):771-7. PubMed ID: 7576744
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Radioactive iodine in differentiated thyroid cancer: a national database perspective.
    Orosco RK; Hussain T; Noel JE; Chang DC; Dosiou C; Mittra E; Divi V; Orloff LA
    Endocr Relat Cancer; 2019 Oct; 26(10):795-802. PubMed ID: 31443087
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcomes after diagnosis of mycosis fungoides and Sézary syndrome before 30 years of age: a population-based study.
    Ai WZ; Keegan TH; Press DJ; Yang J; Pincus LB; Kim YH; Chang ET
    JAMA Dermatol; 2014 Jul; 150(7):709-15. PubMed ID: 24718769
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Risk of primary breast cancer in patients with differentiated thyroid cancer undergoing radioactive iodine therapy: a systematic review and meta-analysis.
    Nappi C; Klain M; Cantoni V; Green R; Piscopo L; Volpe F; Maurea S; Petretta M; Cuocolo A
    Eur J Nucl Med Mol Imaging; 2022 Apr; 49(5):1630-1639. PubMed ID: 34820683
    [TBL] [Abstract][Full Text] [Related]  

  • 53. (131)I treatment for thyroid cancer and the risk of developing salivary and lacrimal gland dysfunction and a second primary malignancy: a nationwide population-based cohort study.
    Ko KY; Kao CH; Lin CL; Huang WS; Yen RF
    Eur J Nucl Med Mol Imaging; 2015 Jul; 42(8):1172-8. PubMed ID: 25900274
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Feasibility Study Shows Multicenter, Observational Case-Control Study Is Practicable to Determine Risk of Secondary Breast Cancer in Females With Differentiated Thyroid Carcinoma Given Radioiodine Therapy in Their Childhood or Adolescence; Findings Also Suggest Possible Fertility Impairment in Such Patients.
    Drozd V; Schneider R; Platonova T; Panasiuk G; Leonova T; Oculevich N; Shimanskaja I; Vershenya I; Dedovich T; Mitjukova T; Grelle I; Biko J; Reiners C
    Front Endocrinol (Lausanne); 2020; 11():567385. PubMed ID: 33193085
    [No Abstract]   [Full Text] [Related]  

  • 55. Salivary gland side effects commonly develop several weeks after initial radioactive iodine ablation.
    Grewal RK; Larson SM; Pentlow CE; Pentlow KS; Gonen M; Qualey R; Natbony L; Tuttle RM
    J Nucl Med; 2009 Oct; 50(10):1605-10. PubMed ID: 19759114
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Increased incidence of second primary malignancy in patients with malignant astrocytoma: a population-based study.
    Wang W
    Biosci Rep; 2019 Jun; 39(6):. PubMed ID: 31138756
    [TBL] [Abstract][Full Text] [Related]  

  • 57. The Effect of Radioactive Iodine Therapy on Ovarian Function and Fertility in Female Thyroid Cancer Patients: A Systematic Review and Meta-Analysis.
    Piek MW; Postma EL; van Leeuwaarde R; de Boer JP; Bos AME; Lok C; Stokkel M; Filipe MD; van der Ploeg IMC
    Thyroid; 2021 Apr; 31(4):658-668. PubMed ID: 33012254
    [No Abstract]   [Full Text] [Related]  

  • 58. The Incidence Characteristics of Second Primary Malignancy after Diagnosis of Primary Colon and Rectal Cancer: A Population Based Study.
    Guan X; Jin Y; Chen Y; Jiang Z; Liu Z; Zhao Z; Yan P; Wang G; Wang X
    PLoS One; 2015; 10(11):e0143067. PubMed ID: 26571301
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Anatomic sites at elevated risk of second primary cancer after an index head and neck cancer.
    Morris LG; Sikora AG; Hayes RB; Patel SG; Ganly I
    Cancer Causes Control; 2011 May; 22(5):671-9. PubMed ID: 21327458
    [TBL] [Abstract][Full Text] [Related]  

  • 60. The incidence of second primary tumors in thyroid cancer patients is increased, but not related to treatment of thyroid cancer.
    Verkooijen RB; Smit JW; Romijn JA; Stokkel MP
    Eur J Endocrinol; 2006 Dec; 155(6):801-6. PubMed ID: 17132748
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 25.